Slides
Page 1
Corporate Presentation Nasdaq: CMPX November 2025
Page 2
This presentation has been prepared by Compass Therapeutics, Inc. ("we," "us," "our," or the “Company”). Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequentlybecomes availableor changes occurring after the date hereof. This presentation contains forward-looking statements. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Compass's financial position to continue advancing its product candidates, expectations about cash runway, business and development plans, and statements regarding Compass's product candidates, including their preclinical and clinical development, therapeutic potential and tolerability profile, and clinical trial milestones such as the expected trial design, timing of enrollment, patient dosing and data readouts, regulatory plans with respect to Compass's product candidates and the therapeutic potential thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass's ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass's ability to identify additional product candidates for development, Compass's ability to develop, initiate and complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this presentation, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the U.S. Securities and Exchange Commission (SEC) available at www.sec.gov, including without limitation Compass's latest Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the SEC. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. This presentation concerns drugs that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). It is currently limited by Federal law to investigationaluse, and no representation is made as to its safety or effectivenessfor the purposes for which it is being investigated. DISCLAIMER 2
Page 3
Compass Corporate Highlights 3 Achieved primary endpoint in Ph 2/3 study in patients with BTC Key secondary endpoints (PFS / OS) expected late Q1 2026 17.1% ORR (p=0.031) in 2L pts with BTC (compared to 5% with FOLFOX in 2L) $1B+ opportunity in BTC in the US (supported by 3rd-party market research) ~85% of 2L pts with BTC currently have no approved therapeutic alternative Three clinical candidates and PD-1xVEGF-A bispecific IND expected Q4 2025 Cash runway into 2028 with $220M at Q3 2025 Well Capitalized Deep Expertise in Antibodies Multi-$B Market Potential Unprecedented Ph 2 Data * ORR = overall response rate; BTC = biliary tract cancer; 2L = 2nd line therapy; PFS = progression free survival; OS = overall survival; IND = Investigational New Drug Application Compelling Data in Pts w/ BTC Tovecimig: DLL4xVEGF-A
Page 4
* Not shown: Investigator Sponsored Trial of tovecimig in 1st line biliary tract cancer Diversified / Robust Pipeline with Multiple Value Inflection Points 4 Program Target Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Tovecimig (CTX-009) DLL4 x VEGF-A CTX-471 CD137 CTX-8371 PD-1 x PD-L1 CTX-10726 PD-1 x VEGF-A VEGF-IO Bispecifics Multiple Colorectal Cancer (monotherapy 3L/4L) Solid Tumors (cohort expansion in NSCLC & TNBC) Basket Study – DLL4+ tumors Biliary Tract Cancer (2L) Solid tumors Basket Study – Post-checkpoint Basket Study – NCAM (CD56)+ Anticipated Milestones 17.1% ORR (met primary endpoint) Late Q1 2026: PFS / OS data Completed (monotherapy activity) H1 2026: Additional indication(s): CRC, Gastric, Ovarian, Renal, HCC Q1 2026: Trial initiation Completed H1 2026: Phase 1 data Q4 2025: Initiate expansion cohorts Q4 2025: IND filing Ongoing
Page 5
LeadershipTeamExperienced in Drug Discovery and Development 5 Bing Gong, PhD SVP, Discovery Research Jon Anderman, JD SVP, General Counsel & Corporate Secretary ThomasJ. Schuetz, MD, PhD President, CEO, & Vice Chairman of the Board Neil Lerner, CPA, MIM SVP, CAO Ian Chia, PhD VP, Business Development Karin Herrera SVP, Clinical Operations James Kranz, PhD VP, CMC Kris Sachsenmeier, PhD VP, Translational Science Barry Shin, JD, MBA EVP, CFO
Page 6
Tovecimig (CTX-009) DLL4 X VEGF-A bispecific antibody
Page 7
Anti-DLL4 MAb DLL4-Notch-1 signaling Anti-VEGF-A MAb VEGF/VEGF-R signaling Targets tumor DLL4 expression and alters perfusion in tumor vessels (novel angiogenesis target) Tovecimig:Bispecificwith Compelling MOA (DLL4 x VEGF-A) 7 Dual blockade: VEGF-A – validated target for blockbuster oncology therapeutics (e.g.: Avastin®) DLL4 (Notch-1 ligand) – mediates resistance to anti-VEGF therapies Bispecific anchors in tumor microenvironment (DLL4) to disrupt angiogenesis Only DLL4 X VEGF bispecific to demonstrate monotherapy activity in patients with CRC and GC1 Disrupts tumor vessel formation (proven anti-angiogenic mechanism) 2x2 target binding valency VEGF-A DLL4 1. Lee, J et. al. 2021, October 7-10. Plenary Presentation AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
Page 8
15% 15% 14% 10% 9% 9% 8% 8% 7% 7% 6% 4% 4% 4% 3% 3% 0% 0% 0% -1% -5% -5% -9% -9% -11% -13% -17% -20% -26% -27% -35% -38% -40% -41% -60 -40 -20 0 20 60 48% 40% 39% 40 30% 23% 80 75% 100 CRC Gastric Other 40 evaluable patients (all Phase 1 patients, 0.3-17.5 mpk) Patient (dosage mpk) Tovecimig: Monotherapy Activity in Ph 1a Data 8 0.3 0.3 12.5 12.5 0.3 2.5 12.5 17.5 12.5 5.0 7.5 7.5 5.0 10.0 15.0 2.5 15.0 12.5 1.0 12.5 12.5 1.0 15.0 17.5 5.0 12.5 0.3 10.0 5.0 12.5 7.5 1.0 2.5 7.5 10.0 12.5 15.0 10.0 12.5 10.0 Tumor Growth (%)
Page 9
Tovecimig: Combination Activity in Ph 1b Data 9 36.8% 22.7% 16.3% 7.4% 0.0% -0.7% -10.4% -12.7% -17.0% -18.3% -19.7% -20.6% -28.0% -31.4% -34.9% -41.4% -61.6% -70.0% -50.0% -60.0% -40.0% -30.0% -20.0% -10.0% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% Tumor Growth (%) Cholangiocarcinoma Colorectal cancer Gastric Pancreatic Other Tovecimig+ paclitaxel or Tovecimig + irinotecan All patients dosed at 10 or 12.5 mg/kg 17 evaluable patients or Paclitaxel combo (paclitaxel)
Page 10
Tovecimig: Phase 2 BTC Data 10 Investigator-assessed responses in single-arm study (paclitaxel combo) -9 -12 -12 -12 -17 -17 -19 -20 -25 -33 -33 -37 -38 -41 -44 -44 -48 -52 -57-60 -50 -40 -30 -20 -10 0 13 14 15 16 221 2 3 -1 -7 -7 Patient Number 4 5 6 7 8 9 10 11 12 Percent tumor decline Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Gallbladder cancer Ampullary cancer RECIST v1.1 Partial Responses 17 18 19 20 21
Page 11
Paclitaxel 80 mg/m2 Days 1, 8 and 15 of every 28-day cycle Tovecimig 10mg/kg Days 1 and 15 Paclitaxel 80 mg/m2 Days 1, 8 and 15 of every 28-day cycle COMPANION-002: Phase 2/3 U.S. BTC Study Registrational-intent study in patients who have received one prior line of therapy 11 Crossover permitted following disease progression Study Treatment – 28 Day Cycles Follow Up Tovecimig+ Paclitaxel n=111 Paclitaxel n=57 Disease progression per RECIST v1.1, as confirmed by Independent Central Radiology Disease progression per RECIST 1.1, as confirmed by Independent Central Radiology Follow-up approx. every 3 months 2:1 Randomization Primary Endpoint: ORR Key Secondary Endpoints: PFS, OS, DoR
Page 12
Progression-Free Survival Overall Survival (RPSFT2) Overall Survival (intent to treat) Topline Safety 80% OS events (134 of 168) triggers analyses of secondary endpoints Fewer deaths in the study than initially projected Reference: ABC-061 study of FOLFOX in patients with BTC treated in the second-line setting ABC-06 Study: <10% OS at 18 months (median OS = 6.2 months) COMPANION-002: >20% OS at >18 months median follow-up (as of Sept 2025) Tovecimig: Ongoing Phase 2/3 – Secondary Endpoints 12 1. PMID: 33798493 2. RPSFT = “Rank Preserving Structural Failure Time,” a statistical method that adjusts for the effect of crossover Secondary Endpoint Analyses: Next Expected Update: Key Secondary Endpoints in late Q1 2026
Page 13
13 COMPANION-002 Study (BTC) Tovecimig + Paclitaxel Paclitaxel Intent-to-Treat Population n=111 n=57 Overall Response Rate (CR+PR) 19 (17.1%) 3 (5.3%) Two-Sided p-value p=0.031 Best Overall Response (RECIST v1.1 by blinded independent radiology review) Complete Response (CR) 1 (0.9%) 0 (0.0%) Partial Response (PR) 18 (16.2%) 3 (5.3%) Stable Disease (SD) 49 (44.1%) 19 (33.3%) Non-CR / Non-PD* 9 (8.1%) 2 (3.5%) Progressive Disease (PD) 18 (16.2%) 24 (42.1%) Not Evaluable (NE)** 16 (14.4%) 9 (15.8%) Tovecimig: Ongoing Phase 2/3 Summary - Primary Endpoint Safety Data: The safety profile of tovecimig in this study to date has been consistent with prior studies. Safety Monitoring: An independent Data Safety Monitoring Committee reviewed safety data at four separate (pre-specified) meetings and recommended continuation of the study with no modification after each meeting. *Non-CR / Non-PD: patients enrolled based on local radiology scan results, but displayed no clearly definable target lesions as determined by independent central radiology. ** Not Evaluable: patients who did not receive a Week-8 scan; these patients are not evaluable for response only, but will be evaluable for PFS/OS analyses.
Page 14
14 Tovecimig: Top-line Ph 2/3 Activity in Patients with BTC (2L) Target Lesion (% change) Paclitaxel Monotherapy Target Lesion (% change) Tovecimig + Paclitaxel Patients Patients
Page 15
Tovecimig: Potential to Become Standard of Care in 2L BTC 151. PMID: 38319896; 2. PMID: 37075781; 3. PMID: 33798493; 4. DOI: 10.1200/JCO.2023.41.4_suppl.540 Line Program N ORR 1L Gem/Cis+ Durv1 341 26.7% 1L Gem/Cis+ Pembro2 533 28.7% 2L ABC-063 81 BSC 0% 81 FOLFOX 5% 2L Tovecimig + Paclitaxel4 111 17.1% (p=0.031) Median Progression Free Survival Median Overall Survival 5.3 m 4.0 m 6.2 m 7.2 m 12.8 m 6.5 m 12.7 m First Line Second Line Months 0 2 4 6 8 10 12 14 *Historical data presented. Tovecimig is investigational, and no head-to-head studies have been conducted. Tovecimig* in 2L PFS / OS Data Expected Late Q1 2026
Page 16
Cancer site Epidemiology- based (SEER) Claims-based (ICD) 3rd Party Mkt. Research Liver & intrahepatic bile duct 15%2 of 42,2401 --- --- Gallbladder & other biliary 12,6101 --- --- Other & unspecific primary 11%3 of 37,3701 --- --- Total Incidence (2023) ~23,0001 ~22,8004 ~25,0005 16 1. PMID: 39817679; 2. Lowe, R, et al. Epidemiology, risk factors, anatomy, and pathology of cholangiocarcinoma. UpToDate, Inc. (2022); 3. PMID: 35484217; 4. Komodo Health x Cholangiocarcinoma Foundation. (2023); 5. CMPX-commissioned market research (2025) 6. PMID: 33825840 Incidence of BTC is Significant and Not Fully Appreciated US BTC incidence projected to grow to ~34,000 patients by 20376 Gallbladder Ampullary Distal Intrahepatic Extrahepatic Perihilar Liver
Page 17
Significant Unmet Needs in Current Treatments for BTC 171. PMID: 38319896; 2. PMID: 37075781; 3. PMID: 33798493; 4. NCCN (2024). Biliary Tract Cancers (version 4.2024); 5. PMID: 37017301; 6. PMID: 33182517; 7. PMID: 38266541 durvalumab (TOPAZ1)1 pembrolizumab (KN-966)2Gem/Cis + Currently Approved SoC Unmet Needs 1L 2L 2-year OS of 24.9%1 Majority of patients will progress FOLFOX chemotherapy3: ORR of 5% 69% ≥Grade 3 AEs 52% ≥Grade 3 AEs in patients receiving BSC in control arm. Non-targetable Targetable FGFR2 alteration (pemigatinib or futibatinib)5 IDH1 alteration (ivosidenib)6 HER2 overexpression (zanidatamab)7 Addressable opportunity for tovecimig in the 2L setting ~85% Chemotherapy*3,4 ~15-20% have limited treatment options ~80-85% of 2L patients
Page 18
2L BTC U.S. Market Potential is >$1 Billion 18 1. CMPX-commissioned market research (2025); 2. PMID: 27829275; 3. Based on Compass Therapeutics’ analysis and PMID: 38319896; 4. PEMAZYRE prescribing information; 5. LYTGOBI prescribing information Annual BTC incidence in the U.S. (~23K+ in 2023)1 ~90% receive 1L treatment (~10% undergo resection but only ~5% are cured after surgery)2 ~70% of 1L patients receive 2L treatment3 Approved 2L targeted therapies4,5 (contraindications include: ocular toxicity, hyperphosphatemia) ~21.7K >15K~23KPatient Numbers* Chemotherapy/ Opportunity for tovecimig Clinical progression ~15% ~85% *Patient numbers are estimates based on Company analysis of references.
Page 19
Indications BTC CRC Gastric/ GEJ Glio- blastoma HCC Ovarian RCC Incidence ~23k1 ~154k1 ~30k2 ~15k3 ~35k2 ~20k1 ~73k4 CTX-009 Clin. Active5 Avastin Approved6 TBD TBD TBD TBD DLL4+ Enriched7 Tovecimig: Potential Solid Tumor Opportunities Indications with approved angiogenic inhibitors and/or tumors that are DLL4 enriched BTC: Biliary tract cancer; CRC: Colorectal cancer; GEJ: Gastroesophageal junction; HCC: Hepatocellular carcinoma; RCC: Renal cell carcinoma 1. Seer database; 2. Cancer.org; 3. National Brain Tumor Society; 4. PMID: 32644401; 5. Lee, J et. al. 2021, October 7- 10. Plenary Presentation AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 6. Avastin prescribing information; 7. PMID: 36223541 Potential for expansion into numerous solid tumor indications 19
Page 20
Further Expansion Opportunities Broad potential expansion into multiple solid tumor indications BTC (1L) Study IST Enrolling MD Anderson Cancer Center investigator sponsored trial in 1L patients Tovecimig added to front line gem / cis / durvalumab BTC (2L) Data Ph 2/3 20 Achieved primary endpoint in Ph 2/3 study PFS / OS data expected late Q1 2026 Tovecimig granted Fast Track Designation in BTC in April 2024 Tovecimig: Strong Near-Term Momentum
Page 21
CTX-471 CD137 agonist
Page 22
22PMID: 36725933, ASCO 2024, Abstract #2535, SITC 2024 Abstract #679 CTX-471: Potential Best-in-Class CD137 Agonist CTX-471: Signals of Activity in Phase 1 Advancing to Ph 2 NCAM (CD56)+ Basket Study Q1 2026 expected initiation CTX-471: Next Generation CD137 Agonist Fully human, IgG4, optimized affinity for agonistic antibody Unique epitope: non-ligand blocking Monotherapy Phase 1a ascending dose study completed MTD defined by immune thrombocytopenia Monotherapy Phase 1b Post-PD-1 Cohort Expansions completed 60 patients with 17 different tumor types enrolled 4 PRs observed: melanoma (3 of 11) and mesothelioma (1 of 4) 1 CR: small cell lung cancer (1 of 3) Potential biomarker of response identified in biopsies: NCAM (CD56)+ tumors were more likely to respond to CTX-471 JCI Insight. 2020;5(5):e133647 CD137L CD137 Urelumab, 3H3 CTX-471 Utomilumab JCI Insight. 2020;5(5):e133647
Page 23
23 CTX-471 treated patient with advanced SCLC had a PET negative complete response after ~3 years on therapy Previously treated with: carboplatin/etoposide plus atezolizumab (1L), and nivolumab (2L) CTX-471: Complete Response in Small Cell Lung Cancer Patient NCAM (CD56) was identified as a potential biomarker of activity in Phase 1 studies of CTX-471 Patients with Clinical Benefit (CR / PR / SD) NCAM Biomarker Patients with Progressive Disease Small Cell Lung Head and NeckMelanomaSmall Cell Lung Melanoma Melanoma Head and Neck Small Cell Lung Melanoma Melanoma Melanoma Head and Neck Head and Neck Month 4 Month 32 Baseline
Page 24
NCAM (CD56) High in Patients with CTX-471 Disease Control NCAM may render tumors sensitive to CTX-471 treatment: proposed mechanism of action 24 NCAM (CD56) “Positive” Tumor Binding of tumor cell to NK cell via NCAM (CD56) NCAM (CD56) “Negative” Tumor No NCAM (CD56) binding to NK cell Infiltration and upregulation of CD137 leading to an activated NK cell CD137 agonism via binding of CTX-471 leading to tumor cell killing 1 2 3 Created with BioRender.com
Page 25
CTX-471: Proposed NCAM (CD56) Basket Trial NET = Neuroendocrine Tumor SCLC Lung NET CRC NET Metastatic Melanoma Glioblastoma Pancreatic NET Prostate NET US 2023 – SEER DatabaseUS 2023 – SEER Database Indication NCAM Pts SCLC* 37,000 Glioblastoma* 14,707 Metastatic/Melanoma 5,610 Pancreatic NET 3,203 Prostate NET 2,883 NSCLC NET 2,383 Colon NET 1,530 TOTAL * ~100% NCAM+ 60,316 25
Page 26
CTX-8371 PD-1 x PD-L1 bispecific antibody
Page 27
Superior Activity Proprietary Structural Design Engineered Synergistic Activity of PD-1 / PD-L1 in Stitchmabs format 27 Mixed lymphocyte reaction (MLR) assay Pembro/Atezo Stitchmab Nivo/Atezo Stitchmab Pembro + Atezo Cocktail Nivo + Atezo Cocktail Pembro vs PD-1 PD-L1 + StitchMabsTM Platform was Utilized to Identify CTX-8371 15 30 0 500 1000 1500 18 21 24 27 Days after tumor cells inoculation Average Tumor Volume (mm3) IgG1 IC Keytruda CTX-8371 Atezolizumab PD-1xPD-L1 v1 PD-1xPD-L1 v2 Keytruda Nivolumab Isotype Control No Ab Control T-cell activation assay MC38-hPD-L1 model implanted in hPD-1/hPD-L1 transgenic mice CTX-8371
Page 28
CTX-8371: Differentiated MoA Leads to Enhanced T-Cell Activation Potentially first-in-class – converting PD-1 positive T-cells into PD-1 negative T-cells 28 PMID: 38379869 Acts as a T-cell Engager Bridges T-cells with APC / tumor cells Converts T-cells into PD-1 negative CD80 engages CD28 (costimulatory receptor) Cleaves Cell Surface PD-1 Frees CD80 from PD-L1 Suppression Tumor Cell / APC T-Cell or NK Cell Blocks PD-1 / PD-L1 Signaling Reverses inhibition of immune response Traditional checkpoint inhibitor MOA PD-1 PD-L1 PD-1 PD-1 PD-L1 CD28 CD80 Novel checkpoint inhibitor mechanisms PD-L1 Stimulates immune response Blocks / eliminates inhibitory pathway CTX-8371 PD-L1
Page 29
Trial Highlights Two deep responses in the first 12 patients New response in a 3rd indication (5th dosing cohort) No DLTs, suggesting a differentiated safety profile Initiating cohort expansion in NSCLC & TNBC Phase 1 Study Design Multiple ascending dose, “3+3” dose-escalation study 5 doses (mg/kg): 0.1 0.3 1.0 3.0 10.0 Post PD-1 or PD-L1 patient population: Melanoma, NSCLC, HNSCC, HL, TNBC Potential for proprietary combination regimens with tovecimigand CTX-471 29 CTX-8371: Development Status NSCLC = non-small cell lung cancer; HNSCC = head and neck squamous cell carcinoma; HL = Hodgkin lymphoma; TNBC = triple negative breast cancer
Page 30
45 mm 18 mm 0 mm CTX-8371: Patient with NSCLC Target Lesion #1 Imaging 30 Non-Small Cell Lung Cancer (n=5) Baseline Week 8 Week 16 Complete resolution of target tumor lesions in one patient after initial pseudo-progression 4th line with 59 mm total target lesion burden @ baseline Stable disease in two patients (7+ and 14+ months) Clinical benefit rate (CBR) of 60%
Page 31
Week 8Baseline 31 20 mm 0 mm 52 mm 0 mm >90% reduction in target tumor lesions in one patient (4th line) 87 mm total @ baseline (3 target lesions) to 7 mm at week 12 Durable response through week 16 Non-target lesions also decreased in size Triple-Negative Breast Cancer (n=3) Right Lobe Nodule (TL #2) Pericardial Mass (TL #3) CTX-8371: Patient with TNBC Target Lesions #2 and #3 Imaging
Page 32
CTX-10726 PD-1 x VEGF-A bispecific antibody
Page 33
33 CTX-10726: Development Pathway CTX-10726: Drug Discovery and Engineering Fully human, glycosylated IgG1 with silenced Fc-γ receptor binding Anti-VEGF Clinically proven mechanism (bevacizumab) Anti-PD-1 Proprietary anti-PD-1 scFv with highly stable structure High affinity, cooperative target binding More potent PD-1 blockade observed preclinically (vs prior published data for other drugs in class*) Leverages clinical experience from CTX-8371 program IND filing expected by Q4 2025 with potential clinical data in 2026 MOA validated by ivonescimab & other PD-1 x VEGF programs Advanced CMC process with commercial-level yields Novel composition of matter IP CTX-10726 Builds on Compass’ Deep VEGF-IO Expertise Anti-VEGF-A Anti-DLL4 Tovecimig CTX-8371 Anti-PD-1 Anti-PD-L1 Anti-PD-1 Anti-VEGF-A CTX-10726 *Comparison based on reported PD-1 blockade data (IC50, nM) for ivonescimab CTX-10726: PD-1 x VEGF-A Bispecific
Page 34
34 Data compares anti-PD-1 arms of ivonescimab and CTX-10726 No human VEGF-A in this experiment CTX-10726: Superior Anti-PD-1 Activity Compared to Ivonescimab Transgenic Mouse Model (MC38) (express human PD-1/PD-L1) CTX-10726 Isotype Control IvonescimabCTX-10726
Page 35
35 CTX-10726: Anti-PD-1 Activity Comparable to Pembrolizumab Transgenic Mouse Model (MC38) (express human PD-1/PD-L1) CTX-10726 Data compares anti-PD-1 arms of pembrolizumab and CTX-10726 No human VEGF-A in this experiment Isotype Control PembrolizumabCTX-10726
Page 36
36 Human NSCLC (HCC827) Xenografts Treated with human PBMCs and indicated antibodies Testing both PD-1 and VEGF-A targeting CTX-10726: Superior Anti-Tumor Effect in Preclinical Studies 0 10 20 30 40 50 60 0 200 400 600 800 1000 Average Tumor Volume (mm3) +/- SEM **** **** CTX-10726 **** P < 0.0001 two-way ANOVA PBS PBMCs hIgG1 (10 mpk) PBMCs CTX-10726 (14 mpk) PBMCs Ivonescimab(14 mpk) PBMCs anti-VEGFA (10 mpk)Treatment window dosing Albu, D. et al., (2025). SITC Annual Meeting, Abstract #1151
Page 37
Key Anticipated Milestones 2025 37 2026 H1 H2 Tovecimig BTC (DLL4 x VEGF-A) 17.1% ORR (p=0.031) Ph 2/3 Data (2L) Q1 2026 Ph 2/3 Data (2L) PFS / OS H2 2026 BLA Filing (2L) Init. Ph 2 IST (1L) Tovecimig (DLL4 x VEGF-A) H1 2026 Init. Ph 2 (DLL4+) CTX-471 (CD137) Q1 2026 Init. Ph 2 (NCAM) CTX-8371 (PD-1 x PD-L1) H1 2026 Ph 1 Dose Esc. + Early Exp. Cohort Data Q4 26 / Q1 27 Ph 1 Exp. Cohort Data CTX-10726 (PD-1 x VEGF-A) Q4 2025 Preclin. Data & File IND H1 2026 Init. Ph 1 H2 2026 Ph 1 Data
Page 38
Website: compasstherapeutics.com Nasdaq: CMPX Compass Therapeutics